Remetinostat (Standard)

Remetinostat (Standard) is the analytical standard of Remetinostat (HY-100365) . This product is intended for research and analytical applications. Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180) -induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma[1][2].

Product Specifications

CAS Number

[946150-57-8]

Target

HDAC; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Others

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(OC)C1=CC=C(OC(CCCCCCC(NO)=O)=O)C=C1

Molecular Formula

C16H21NO6

Molecular Weight

323.34

References & Citations

[1]Yijun Deng, et al. Process Development of the Soft Histone Deacetylate Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.|[2]Jin L, et al. Topical histone deacetylase inhibitor remetinostat improves IMQ-induced psoriatic dermatitis via suppressing dendritic cell maturation and keratinocyte differentiation and inflammation. Eur J Pharmacol. 2024 Nov 15;983:177011.